Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »

As part of the National Institute for Health and Care Excellence’s (NICE’s) Single Technology Appraisal (STA) process, Novartis submitted evidence on the clinical effectiveness and cost-effectiveness of tisagenlecleucel for treating paediatric and young adult patients (under the age of 25 years) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia

PharmacoEconomics 2019 37: 1209. /  Walton, M., Sharif, S., Simmonds, M. et al.

The development of cluster of differentiation (CD)-19-targeted chimeric antigen receptor (CAR) T cells for the treatment of pre-B-cell acute lymphoblastic leukemia (B-ALL) is an exciting new advancement in the field of pediatric oncology. Tisagenlecleucel and axicabtagene ciloleucel are the first US FDA-approved CD19-targeted CAR T cells. While various different CD19 CAR T cells are

Paediatr Drugs. 2019 Nov 20.[Epub ahead of print] /  Pacenta HL, Laetsch TW, John S, et al.

Purpose of review:  Chimeric antigen receptor (CAR)-T-cell therapy is a revolutionary tool in the treatment of cancer. CAR-T cells exhibit their effector functions through the recognition of their specific antigens on tumor cells and recruitment of other immune cells. However, this therapy is limited by the development of severe toxicities and modest

Curr Opin Hematol 2019 Nov 19 [Epub ahead of print] /  Sterner RM, Kenderian SS.

Objective: Older adults in long-term care (LTC) are often frail, comorbid, and have multiple medications. Pharmacist review of medications has been integrated into LTC practice in many countries through policy and reimbursement models, but the impact is variable in the literature. The purpose of our study was to review the

 Journal of the American Pharmacists Association 2019; /  Sadowski P, Charrois CA, Sehn TL, et al.

Chimeric antigen receptor T-cells are a novel class of anti-cancer therapy in which autologous or allogeneic T-cells are engineered to express a chimeric antigen receptor targeting a membrane antigen. In Europe, Tisagenlecleucel (KymriahTM) is approved for the treatment of refractory/relapsed Acute Lymphoblastic Leukaemia in children and young adults as well

Haematologica 2019 Nov 21 [Epub ahead of print] /  Yakoub-Agha I, Chabannon C, Bader P, et al.

Summary: Research suggests various inventory optimization models, which can lead to cost reductions while maintaining adequate service levels; however, they are facing limited adoption in healthcare settings. The main barriers appear to be the high effort and complexity of implementation, the dependence on data that are not available or might

Am J Health Syst Pharm 2019 Nov 22. [Epub ahead of print] /  Bialas C, Revanoglou A, Manthou V, et al.

Background: Clinicians prescribe high-cost medicines for rare diseases and nonapproved indications when conventional therapies have failed. Objective To examine the use of non-formulary high-cost medicines at an Australian public hospital. Methods Retrospective audit of individual patient use applications for nonformulary medicines costing more than $5000 AUD per year at a

Int J Clin Pharm 2019; 920-931. /  Inglis JM, Caughey GE, Shakib S, et al.

Background: Drug-related problems (DRP) following hospital discharge may cause morbidity, mortality and hospital re-admissions. It is unclear whether a clinical medication review (CMR) and counseling at discharge is a cost-effective method to reduce DRP. Objective: To assess the effect of a CMR on health care utilization and to investigate whether CMR

Int J Clin Pharm 2019 ;41(4):963-971. /  van der Heijden AAWA, de Bruijne MC, Nijpels G, et al.

Purpose: The aim of this study is to understand the frequency of appropriate laboratory monitoring of oral chemotherapy at the Eastern Colorado Health Care System (ECHCS) compared to recommendations set forth in the 2012 Veterans Health Administration (VHA) Guidance on Dispensing and Monitoring of Oral Chemotherapy. Methods: This study is a

J Oncol Pharm Pract. 2019 First Published November 4, 2019 /   Heck JN, Null AA

Purpose: Existing studies evaluating patient adherence to oral targeted therapies such as tyrosine kinase inhibitors focus on small populations with single malignancies. This study evaluated patterns of use of oral agents in a larger population across multiple hematologic malignancies. Methods: Adult patients diagnosed with a hematologic malignancy and prescribed oral targeted therapy between 2011 and 2016 (N = 18,976) were identified from the MarketScan Commercial Claims and Encounters, and Medicare Supplemental databases.

J Oncol Pharm Pract. 2019:1897-1906. /  Patel K, Sudhir VS, Kabadi S, et al.